Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs

Inclusion Criteria: * Male or female, ages \> 7 years old * Diagnosis of CF as evidenced by sweat chloride test and/or genetic mutation testing * Sputum SA CFUs \> 10,000 per mL * Ability to expectorate sputum * Ability to tolerate nasal lavage and collection of breath condensate * Willing to practice reliable birth control measures during the entire study period, if subject is of childbearing potential * Informed consent obtained from subject or legal guardian, and assent if appropriate Exclusion Criteria: * Burkholderia cepacia in sputum * Subjects who have had changes to their treatment regimen for CF in the past 6 weeks * Subjects can be screened 6 weeks after IV antibiotic completion * Subjects can be screened 7 days after oral antibiotic completion * Received an investigational drug within 30 days of study entry * Received any immune globulin or blood product within 30 days of study entry * History of hypersensitivity to immune globulin preparations * Undergoing any type of dialysis or expected to start dialysis within 30 days * Pregnant or nursing females * Considered unlikely to comply with the study procedures or to return for scheduled post-treatment evaluations